Drug Profile
BPI 3016
Alternative Names: BPI-3016Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Betta Pharmaceuticals Co Ltd
- Class Antihyperglycaemics; Glucagon-like peptides
- Mechanism of Action Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in China (SC, Injection)
- 29 Dec 2018 Phase-I clinical trials in Type 2 diabetes mellitus (In volunteers) in China (SC) (NCT03188848)
- 13 Jun 2017 Betta Pharmaceuticals plans a phase I trial for Type-2 diabetes mellitus (In volunteers, In adults) in China (NCT03188848)